Table 3. Summary of finding.
| Outcome | EGFR mutation | Subgroup | Studies | Statistical method | Effect estimate |
|---|---|---|---|---|---|
| PFS | Deletion 19 | Overall | 8 | Hazard ratio (IV, random, 95% CI) | 0.27 (0.21–0.35) |
| Reversible TKI (erlotinib, gefitinib) | 6 | Hazard ratio (IV, random, 95% CI) | 0.28 (0.20–0.40) | ||
| Irreversible TKI (afatinib) | 2 | Hazard ratio (IV, random, 95% CI) | 0.24 (0.17–0.33) | ||
| TKI vs cisplatin-based chemotherapy | 4 | Hazard ratio (IV, random, 95% CI) | 0.27 (0.19–0.39) | ||
| TKI vs carbiplatin-based chemotherapy | 3 | Hazard ratio (IV, random, 95% CI) | 0.26 (0.15–0.48) | ||
| L858R | Overall | 8 | Hazard ratio (IV, random, 95% CI) | 0.45 (0.35–0.58) | |
| Reversible TKI (erlotinib, gefitinib) | 6 | Hazard ratio (IV, random, 95% CI) | 0.44 (0.34–0.57) | ||
| Irreversible TKI (afatinib) | 2 | Hazard ratio (IV, random, 95% CI) | 0.48 (0.22–1.09) | ||
| TKI vs cisplatin-based chemotherapy | 4 | Hazard ratio (IV, random, 95% CI) | 0.51 (0.36–0.73) | ||
| TKI vs carbiplatin-based chemotherapy | 3 | Hazard ratio (IV, random, 95% CI) | 0.36 (0.23–0.56) | ||
| OS | Deletion 19 | Overall | 5 | Hazard ratio (IV, random, 95% CI) | 0.72 (0.60–0.88) |
| Reversible TKI (erlotinib, gefitinib) | 3 | Hazard ratio (IV, random, 95% CI) | 0.84 (0.69–1.02) | ||
| Irreversible TKI (afatinib) | 2 | Hazard ratio (IV, random, 95% CI) | 0.59 (0.47–0.73) | ||
| TKI vs cisplatin-based chemotherapy | 2 | Hazard ratio (IV, random, 95% CI) | 0.59 (0.47–0.73) | ||
| TKI vs carbiplatin-based chemotherapy | 2 | Hazard ratio (IV, random, 95% CI) | 0.81 (0.64–1.02) | ||
| L858R | Overall | 5 | Hazard ratio (IV, random, 95% CI) | 1.15 (0.95–1.39) | |
| Reversible TKI (erlotinib, gefitinib) | 3 | Hazard ratio (IV, random, 95% CI) | 1.06 (0.76–1.49) | ||
| Irreversible TKI (afatinib) | 2 | Hazard ratio (IV, random, 95% CI) | 1.25 (0.99–1.60) | ||
| TKI vs cisplatin-based chemotherapy | 2 | Hazard ratio (IV, random, 95% CI) | 1.25 (0.99–1.60) | ||
| TKI vs carbiplatin-based chemotherapy | 2 | Hazard ratio (IV, random, 95% CI) | 1.09 (0.69–1.90) |
Abbreviations: CI=confidence interval; EGFR=epidermal growth factor receptor; IV=inverse variance; OS=overall survival; PFS=progression-free survival; TKI=tyrosine kinase inhibitor.